Last reviewed · How we verify
CIIIT
CIIIT is a small molecule that targets the SGLT2 receptor.
CIIIT is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes, Cardiovascular risk reduction in patients with type 2 diabetes.
At a glance
| Generic name | CIIIT |
|---|---|
| Sponsor | Joslin Diabetes Center |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
By inhibiting SGLT2, CIIIT reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes. CIIIT's SGLT2 inhibition also has a secondary effect of reducing sodium reabsorption, which may contribute to its cardiovascular benefits.
Approved indications
- Type 2 diabetes
- Cardiovascular risk reduction in patients with type 2 diabetes
Common side effects
- Increased risk of diabetic ketoacidosis
- Genital yeast infections
- Increased risk of amputations
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |